Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis

References

• Tan EM. Special antibodies for the study of systemic lupus erythe-matosus and analysis. Arthritis Rheum 1982;25:753–6.
   PubMedGoogle Scholar
• Harmon C. Antinuclear antibodies in autoimmune disease: signifi-cance and pathogenicity. Med Clin North Am 1985;69:547–63.
   PubMed Web of Science ®Google Scholar
• Koffler D, Miller TE, Fairferman I. Antipoly-nucleotide antibod-ies: the rheumatic connection. Hum Pathol 1983;14:406–18.
   Google Scholar
• Tan EM. Antinuclear antibodies in diagnosis and management. Hosp Pract 1983;18:78–84.
   Google Scholar
• Tan EM, Portonova JP. The role of histones as nuclear autoanti-gens in drug-related lupus erythematosus. Arthritis Rheum 1981;24:1064–9.
   PubMedGoogle Scholar
• Kotzin B. L. Systemic lupus erythematosus. Cell 85: 303.
   Google Scholar
• Gladman DD, Urowitz MB. Prognosis, mortality, and morbidity in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, edi-tors. Dubois' lupus erythematosus. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 1255–73.
   Google Scholar
• Takei S, Maeno N, Shigemori M, Imanaka H, Mori H, Nerome Y, et al. Clinical features of Japanese children and adolescents with systemic lupus erythematosus: results of 1980-1994 survey. Acta Pediatr Jpn 1997;39:250–6.
   PubMedGoogle Scholar
• Gibbons RB, Westerman E. Acute nonlymphocytic leukemia fol-lowing short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis. Arthritis Rheum 1988;31:1552–4.
   PubMedGoogle Scholar
• Vasquez S, Kavanaugh AF, Schneider NR, Wacholtz MC, Lipsky PE. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Ftheuma-tol 1992;19:1625–7.
   Google Scholar
• Boumpas DT, Austin HA, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741–5.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophospha-mide therapy. Ann Intern Med 1993;119:366–9.
   PubMed Web of Science ®Google Scholar
• McDermott EM, Powell RJ. Incidence of ovarian failure in sys-temic lupus erythematosus after treatment with pulse cyclophos-phamide. Ann Rheum Dis 1996;55:224–9.
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophos-phamide therapy. Arthritis Rheum 1998;41:831–7.
   PubMed Web of Science ®Google Scholar
• Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725–34.
   PubMed Web of Science ®Google Scholar
• Feutren G. Cyclosporine A: recent development in the mecha-nisms of action and clinical application. Curr Opin Immunol 1989; 2:239–45.
   PubMedGoogle Scholar
• Bloemena E, van Oers MH, Weinreich S, Yong SL, Schellekens PT. Prednisolone and cyclosporin A exert differential inhibitory effects on T-cell proliferation in vitro. Clin Immunol Immuno-pathol 1988;48:380–91.
   PubMedGoogle Scholar
• Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, et al. Cyclosporin A in patients receiving renal allografts from ca-daver donors. Lancet. 1978;2:1323–7.
   PubMed Web of Science ®Google Scholar
• Mountz JD, Smith HR, Wilder RL, Reeves JP, Steinberg AD. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopa-thology despite autoantibody production. J Immunol 1987;138: 157–63.
   Google Scholar
• Hochberg MC. Updating American College of Ftheumatology re-vised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549–57.
   Google Scholar
• Valeri A, Radhakrishnan J, Estes D, D'Agati V, Kopelman R, Pernis A, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994;42:71–8.
   Google Scholar
• Isenberg DA, Snaith ML, Morrow WJ, Al-Khader AA, Cohen SL, Fisher C, et al. Cyclosporin A for the treatment of systemic lupus erythematosus. Int J Immunopharmacol 1981;3:163–9.
   PubMed Web of Science ®Google Scholar
• Deteix P, Lefrancois N, Lavine M, Colon S, Zech P, Traeger J. Open therapeutic trial of cyclosporin in systemic lupus erythema-tosus. Preliminary results in 4 patients. In: Schindler R, editor. Cyclosporin in autoimmune diseases. Berlin: Springer; 1985. p. 361–5.
   Google Scholar
• Awni WM. Pharmacodynamic monitoring of cyclosporin. Clin Pharmacokinet 1992;23:428–48.
   PubMedGoogle Scholar
• Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, et al. Effect of low-dose cyclosporin A on systemic lupus erythe-matosus disease activity. Arthritis Rheum. 1994;37:551–8.
   PubMed Web of Science ®Google Scholar
• Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclospo-rin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Ftheumatol 1998;37:217–21.
   PubMedGoogle Scholar
• Morton SJ, Powell RJ. An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use. Ann Rheum Dis 2000;59:487–9.
   PubMed Web of Science ®Google Scholar
• Erdem Y, Yalcin AU, Oymak 0, Yasavul U, Turgan C, Caglar S. Cyclosporin A in lupus nephritis. Nephron 1996;72:332.
   Google Scholar
• Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Ftheumatol 1996;35:669–75.
   Google Scholar
• Dostal C, Tesar V, Rychlik I, Zabka J, Vencovsky J, Bartunkova 35. J, et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998;7: 29–36.36.
   Google Scholar
• Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, et al. Long-term treatment of lupus nephritis with cyclosporin A. Q J Med 1998;91:573-80.37.
   Google Scholar
• Radhakrishnan J, Kunis CL, D'Agati V, Appel GB. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994;42:147–54.
   Google Scholar
• Olshan AF, Mattison DR, Zwanenburg TS. International Commis- 38. sion for Protection Against Environmental Mutagens and Carcino-gens. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Mutat Res 1994;317: 163–73.
   Google Scholar
• Doria A, Di Lenardo L, Vario S, Calligaro A, Vaccaro E, Gambari PF. Cyclosporin A in a pregnant patient affected with systemic lu-pus erythematosus. Ftheumatol Int 1992;12:77–8.
   PubMedGoogle Scholar
• Hussein MM, Mooij JM, Roujouleh H. Cyclosporine in the treat-ment of lupus nephritis including two patients treated during preg-nancy. Clin Nephrol 1993;40:160–3.
   Google Scholar
• Israel-Biet D, Noel LH, Bach MA, Dardenne M, Bach JF. Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin A treated (NZB X NZW) Fl mice. Clin Exp Immunol 1983;54:359–65.
   Google Scholar
• In S, Dueymes M, Appolinaire-Pilipenko S, Sournies F, Labarre JF, Fournie GJ. Treatment of end stage MRL-lpr/lpr mouse lupus disease by a cyclophosphazene derived drug and by cyclosporin A. J Clin Lab Immunol 1990;32:85–90.
   Google Scholar